Expand PFE Menu
PFE MENU

PFE Latest Press Releases

-- November 21, 2024 --

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO (Sulbactam-Durlobactam) Business Wire 4:00 AM

-- November 20, 2024 --

Pfizer Announces New Chief Scientific Officer and President, Research & Development Business Wire 6:45 AM
European Commission Approves Pfizer's HYMPAVZI (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors Business Wire 4:00 AM

-- November 14, 2024 --

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

-- November 11, 2024 --

ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Nave People With Advanced HIV Business Wire 9:30 AM

-- November 7, 2024 --

ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow Business Wire 9:19 AM

-- November 4, 2024 --

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

-- October 29, 2024 --

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance Business Wire 6:45 AM

-- October 23, 2024 --

Advisory Committee on Immunization Practices Recommends PREVNAR 20 (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older Business Wire 4:45 PM

-- October 22, 2024 --

U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO for Adults Aged 18 to 59 at Increased Risk for Disease Business Wire 4:45 PM
Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit Business Wire 8:55 AM

-- October 16, 2024 --

ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024 Business Wire 7:01 AM

-- October 15, 2024 --

Tim Buckley Elected to Pfizer's Board of Directors Business Wire 6:45 AM

-- October 11, 2024 --

U.S. FDA Approves Pfizer's HYMPAVZI (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors Business Wire 1:23 PM

-- October 10, 2024 --

Starboard Value Issues Letter to Pfizer's Board of Directors Business Wire 8:45 AM
Pfizer's TALZENNA in Combination with XTANDI Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial Business Wire 6:51 AM

-- October 9, 2024 --

Pfizer Declares Fourth-Quarter 2024 Dividend Business Wire 4:30 PM

-- October 8, 2024 --

Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024 Business Wire 4:45 PM

-- October 7, 2024 --

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries Business Wire 7:00 AM

-- September 25, 2024 --

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA (voxelotor) From Worldwide Markets Business Wire 5:00 PM

-- September 20, 2024 --

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs Globe Newswire 9:00 AM
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union Business Wire 8:11 AM
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union Globe Newswire 8:10 AM

-- September 17, 2024 --

Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts Business Wire 10:00 AM

-- September 14, 2024 --

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia Business Wire 8:45 AM
Pfizer's BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Business Wire 4:15 AM

-- September 11, 2024 --

Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 Business Wire 6:45 AM
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 PRNewswire 2:01 AM

-- September 10, 2024 --

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors Business Wire 7:00 AM

-- September 4, 2024 --

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 Globe Newswire 8:30 AM

-- September 3, 2024 --

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate Globe Newswire 1:00 AM

-- August 28, 2024 --

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire 10:00 AM

-- August 27, 2024 --

Pfizer Launches PfizerForAll , a Digital Platform that Helps Simplify Access to Healthcare Business Wire 6:45 AM

-- August 22, 2024 --

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine Globe Newswire 2:15 PM
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine Business Wire 2:15 PM

-- August 16, 2024 --

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age Globe Newswire 6:45 AM
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age Business Wire 6:45 AM

-- August 12, 2024 --

Pfizer Announces Top-Line Results of ABRYSVO for RSV in Immunocompromised Adults Business Wire 6:45 AM

-- August 6, 2024 --

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 Globe Newswire 8:30 AM

-- July 30, 2024 --

Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance Business Wire 6:45 AM

-- July 25, 2024 --

European Commission Approves Pfizer's DURVEQTIX (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B Business Wire 10:48 AM
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected Globe Newswire 8:30 AM

-- July 24, 2024 --

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate Business Wire 6:45 AM

-- July 23, 2024 --

ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1 Business Wire 4:06 AM

-- July 17, 2024 --

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion Globe Newswire 4:00 PM
CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts Business Wire 8:00 AM

-- July 15, 2024 --

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024 Business Wire 8:32 AM

-- July 11, 2024 --

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron Business Wire 6:45 AM

-- July 9, 2024 --

Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development Business Wire 6:45 AM

-- July 1, 2024 --

Cyrus Taraporevala Elected to Pfizer's Board of Directors Business Wire 6:45 AM